Search

Search. Home. Fellow partners with AstraZeneca to advance the treatment of lupus. ... possibilities for treating patients with systemic lupus erythematosus (also known as SLE or lupus).

47:03","modified_gmt":"2017-07-17T09:47:03","slug":"human-antibodies-developed-for-treatment-of-lupus-and-anthrax","status":"publish","type":"post","link":"https://www2.mrc-lmb.cam.ac.uk/ ... human-antibodies-developed-for-treatment-of-lupus-and-anthrax/"

30:55","modified_gmt":"2012-06-29T08:30:55","slug":"new-drug-benlysta-in-lupus-treatment","status":"publish","type":"post","link":"https://www2.mrc-lmb.cam.ac.uk/new-drug-benlysta- ... in-lupus-treatment/","title":{"rendered":"New drug Benlysta in Lupus

15:11","modified_gmt":"2017-10-31T14:15:11","slug":"human-antibody-approved-for-treatment-of-lupus","status":"publish","type":"post","link":"https://www2.mrc-lmb.cam.ac.uk/human-antibody- ... approved-for-treatment-of-lupus/","title":{"rendered":"Human

New drug Benlysta in Lupus treatment. ... Published on. 15 June, 2011. “Benlysta emerges as a direct approach in lupus treatment.

2022: Fellow Prof. Rahul Roychoudhuri signs a partnership with AstraZeneca to advance the treatment of lupus.

for treatment of lupus. ... Published on. 11 March, 2011. Systemic lupus erythematosus is a chronic, life-threatening inflammatory autoimmune disease that can cause debilitating fatigue, painful and swollen joints, fever, skin rash, and kidney problems.

Yonath (Weizmann Institute of Science, Israel). The trio showed how the information encoded on strands of DNA […]. Human Antibodies developed for Treatment of Lupus and Anthrax. ... treat lupus, a potentially fatal autoimmune disease, and anthrax, a

{"id":4193,"date":"2013-01-07T13:50:34","date_gmt":"2013-01-07T13:50:34","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/research/technology-transfer/history-of-technology-transfer/"},"modified":"2023-07-21T12:49:41","modified_gmt":"2023-

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. ... Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).